Brainstorm Cell Therapeutics (BCLI)
0.33
0.00 (0.00%)
Upcoming Events
Latest Headlines
Form 4 BRAINSTORM CELL THERAPEU For: Mar 11 Filed by: Lindborg Stacy
March 13, 2024 8:58 PM - SEC Filing
Form 4 BRAINSTORM CELL THERAPEU For: Mar 11 Filed by: Yablonka Uri
March 13, 2024 8:57 PM - SEC Filing
Form 4 BRAINSTORM CELL THERAPEU For: Mar 11 Filed by: Patlis Alla
March 13, 2024 8:56 PM - SEC Filing
Form 4 BRAINSTORM CELL THERAPEU For: Mar 11 Filed by: Lebovits Chaim
March 13, 2024 8:55 PM - SEC Filing
Brainstorm Cell Therapeutics (BCLI) to Unveil Phase 3b NurOwn Trial Design at MDA Clinical and Scientific Conference
February 27, 2024 6:32 AM - StreetInsider
BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn® Trial Design at MDA Clinical and Scientific Conference
February 27, 2024 6:30 AM - PR NewsWire
Brainstorm Cell Therapeutics (BCLI) Submits SPA Request to FDA for US Phase 3b Trial of NurOwn
February 23, 2024 6:00 AM - StreetInsider
BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALS
February 23, 2024 6:00 AM - PR NewsWire
BrainStorm Cell Therapeutics to Present at European Life Sciences CEO Forum
February 13, 2024 6:30 AM - PR NewsWire
Form SC 13G/A BRAINSTORM CELL THERAPEU Filed by: Ness Kevin Dean
February 12, 2024 10:06 AM - SEC Filing
BCLI FINAL DEADLINE TOMORROW: ROSEN, A TOP RANKED LAW FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors with Losses in Excess of $500K to Secure Counsel Before Important January 2 Deadline
January 1, 2024 1:55 PM - StreetInsider
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Brainstorm Cell, SolarEdge, and Barclays and Encourages Investors to Contact the Firm
December 28, 2023 9:00 PM - StreetInsider
BCLI DEADLINE ALERT: ROSEN, LEADING INVESTOR COUNSEL, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important January 2 Deadline in Securities Class Action Commenced
December 28, 2023 5:03 PM - StreetInsider
BRAINSTORM SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Brainstorm To Contact Him Directly To Dis
December 27, 2023 9:30 AM - StreetInsider
Brainstorm Cell Therapeutics (BCLI) Granted Patents for Allogeneic Exosome Platform-Product in Neurological Disorder Treatments
December 26, 2023 7:30 AM - StreetInsider
BrainStorm Granted Patents for Allogeneic Exosome Platform-Product in Neurological Disorder Treatments
December 26, 2023 7:30 AM - PR NewsWire
BRAINSTORM CELL ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Brainstorm Cell Therapeutics Inc. and Encourages Investors to Contact the Firm
December 24, 2023 9:00 PM - StreetInsider
BRAINSTORM CELL ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Brainstorm Cell Therapeutics Inc. and Encourages Investors to Contact the Firm
December 20, 2023 9:00 PM - StreetInsider
Form 8-K BRAINSTORM CELL THERAPEU For: Dec 18
December 20, 2023 5:05 PM - SEC Filing
Brainstorm Cell Therapeutics (BCLI) Issues 2023 Letter to Shareholders
December 20, 2023 9:01 AM - StreetInsider
BrainStorm Issues 2023 Letter to Shareholders
December 20, 2023 9:00 AM - PR NewsWire
Full Article List